Search companies

Live

Tuesday, 17 November 2026 · 577 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Mesoblast Revenue Rises 44% as Operating Cash Spend Falls 86%

MSB: $2.32 +23.40% · MC: $2.6B

Mesoblast reported first-quarter Ryoncil net revenue of US$28 million, up 44% from a year earlier, while operating cash spend fell 86% to approximately US$2 million. The company held US$99 million in cash at quarter-end. It completed treatment of all patients in its pivotal chronic low back pain trial, with the primary result expected next year, and began enrolling adults in a Ryoncil registration trial. The FDA also confirmed that a planned application for rexlemestrocel-L may proceed for certain heart failure patients with life-threatening gastrointestinal bleeding.

Source announcements: 2026-10-29 09:54 to 2026-10-29 09:54 Sydney time
Story updated 2026-10-29 10:38 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments